Incyte's partnership with Syndax Pharmaceuticals on the development of axatilimab could potentially boost Incyte's value, especially given the positive outlook from Guggenheim Partners. However, as the partnership is with Syndax, the direct impact on Incyte may be less pronounced.

The BUY rating and high price target from Guggenheim Partners indicate a positive outlook for Syndax Pharmaceuticals. The company's lead asset, revumenib, is seen as a potential breakthrough in the treatment of certain leukemias, which could significantly boost the company's value. Additionally, the company's second program, axatilimab, partnered with Incyte, is also seen as a valuable asset.